Palliative Radiotherapy in Skeletal Metastasis

Not Applicable

Registration Number: CTRI/2024/08/072042

Lead Sponsor: Homi Bhabha Cancer Hospital and Research Center, Tata Memorial Centre, Visakhapatnam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

a. Patients with histologically confirmed malignancy with symptomatic metastatic bone disease detected on cross sectional imaging

b. If bone metastases are asymptomatic or minimally symptomatic (without opioid need) will be considered as high risk bone metastases if any of the following criteria is met:

1. More than 50% cortical destruction

2. More than 3 cm maximum diameter

3. Axila cortical involvement more than 3 cm

4. Multifocal lytic disease

Exclusion Criteria

1. Patients who had previously received radiation therapy in the study region concerned.

2. Patients with any comorbidities that attributes to the present symptoms (intervertebral disc prolapse, spinal cord compression, and fractures post-spinal fixation)

3. Leptomeningeal disease.

4. Serious medical co-morbidities that preclude RT.

5. Patients who are diagnosed with prostate & haematolymphoid malignancy.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To Assess incidence of Skeletal Related events (SRE)Timepoint: 6 months

Secondary Outcome Measures

Name	Time	Method
To document post-radiation acute toxicitiesTimepoint: 3 months;To document post-radiation late toxicitiesTimepoint: 12 months;To Evaluate pain response in patients with Symptomatic bone metastasisTimepoint: 6 months;To evaluate patterns of analgesic usage in patients with symptomatic bone metastasisTimepoint: 6 months